This roundtable series evaluates the use of frontline immunotherapy plus chemotherapy in locally advanced or metastatic biliary tract cancer, as discussed by key opinion leaders and participants at virtual live events.
TOPAZ-1 Data Support New Frontline Option in Patients With BTC
January 30th 2023During a Targeted Oncology case-based roundtable event, Nilofer S. Azad, MD, discussed the data supporting the previous standard of care and the new frontline regimen of gemcitabine, cisplatin, and durvalumab for patients with biliary tract cancers.